Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: HER2+ Breast Cancer
March 25, 2021
The HER2+ breast cancer market will grow between 2021 and 2025, with rising sales in the US, Japan, and five major European markets
(France, Germany, Italy, Spain, and the UK); however, the market will experience a slight downturn after 2025 as key brands Perjeta and Kadcyla
face biosimilar erosion across all regions. Furthermore, the market for HER2+ breast cancer is also becoming increasingly crowded, creating fierce
competition among approved and pipeline therapies.
High prices for combination regimens will translate to high revenues, despite the introduction of biosimilars. The increased use of combination regimens, in conjunction with the continued uptake of novel branded therapies and rising disease prevalence, will partially offset the decrease in revenues caused by biosimilars over the forecast period.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Breast Cancer|